SLC1A2 and central nervous system cancer: Glioma cells utilize a similar mechanism by under-expressing EAAT2 and increasing glutamate release, creating a toxic microenvironment, increasing astrocyte EAAT2-deficiency, and conferring survival and migratory advantages [29].